CombiMatrix Appoints Daniel R. Forche As Senior Vice President Of Sales And Marketing -- Provides Market Update
IRVINE, Calif., Oct. 20, 2010 (GLOBE NEWSWIRE) -- CombiMatrix Corporation (Nasdaq:CBMX) announced today that it has appointed Daniel R. Forche as Senior Vice President of Sales and Marketing. Mr. Forche has deep and broad experience in the molecular diagnostics industry and joins CombiMatrix from Agendia Inc. where he held the position of Vice President of Sales and Marketing. "We are delighted to have retained Mr. Forche for this position," stated R. Judd Jessup, President and CEO of CombiMatrix Corporation. "Mr. Forche's impressive track record and vast industry knowledge will be essential to our management team as we move the company to the next level of commercialization."
"I am excited about this opportunity at CombiMatrix," noted Mr. Forche. "With the company's current technology platforms and molecular expertise, CombiMatrix is well positioned to meet the growing demand for its products and services. I look forward to working with the management team and driving the business to the next level," concluded Mr. Forche.
Mr. Forche has over 18 years of commercial experience in the sales and marketing of diagnostic products and services at both large and small companies. Most recently, Mr. Forche served as Vice President of Sales and Marketing for Agendia Inc. where he was responsible for building the U.S. sales team and driving revenue growth. From 2001 to 2006, he held various roles including Vice President of Marketing and Oncology Sales for US LABS. Mr. Forche's experience also includes positions with Ventana Medical Systems Abbott Laboratories' Diagnostics Division and InSight Health Corp."With the addition of Mr. Forche to CombiMatrix, we look forward to growing our business by focusing on the Constitutional and Oncology segments within the emerging molecular diagnostics markets in the U.S.," continued Mr. Jessup. "CombiMatrix holds a unique position in both the Constitutional and Oncology segments of the molecular diagnostics market through the offering of proprietary and high density array platforms for DNA-based comprehensive genomic analysis. In January 2010, CombiMatrix became the first clinical laboratory in the United States to make comprehensive array-based genomic profiling of solid tumors routinely available to all oncology patients. Since the launch of this service, we have profiled a growing number and variety of solid tumors including breast, brain, colon, lung, and melanoma. This unique ability to produce a full genomic signature on DNA extracted from formalin fixed solid tumor tissue has aided oncologists in their delivery of personalized patient care, and positioned CombiMatrix to increase test volume from other clinical laboratories as well as medical practices specializing in cancer," concluded Mr. Jessup.
Select the service that is right for you!COMPARE ALL SERVICES
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
- Real Money + Doug Kass + 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV